Cyclica Inc (Cyclica) designs and develops advanceable molecules for various disease targets. The company is investigating programs for oncology and central nervous system (CNS) disorders. Its platform technology consists of MatchMaker, an AI-enabled deep-learning engine that predicts the polypharmacology of small molecules for drug discovery.

Cyclica’s POEM (Pareto Optimal Embedding Model) engine is a unique similarity-based property prediction model that utilizes multiple types of fingerprints to describe molecules. The company’s platform uses a proteome-wide lens to understand molecule properties and evaluate novel and rare on-target and off-target interactions.

It works in partnership with Vyant Bio, AstraZeneca, Cereval, and other pharmaceutical and biotechnology companies. Cyclica is headquartered in Toronto, Ontario, Canada.